ACAndrew Cheung

Andrew Cheung

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andrew Cheung has a total of 231 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • No Reflow at Perfusion Imaging: Thresholds That Distinguish Functional and Tissue Outcome Groups in Acute Stroke

    by Tianqi Xu, Chushuang Chen, Nathan W. Manning, Andrew K. Cheung, Dennis J. Cordato, Christopher Blair, Beom Joon Kim, Jianhong Yang, Gang Li, Mark Parsons, et al.

    In patients with successful angiographic recanalization after endovascular thrombectomy (EVT), the presence of a lesion with delay time longer than 4 seconds appeared to be the most informative no-reflow definition at 24-hour post-EVT CT or MR perfusion imaging.


  • Eligibility for Thrombolysis for Pediatric Acute Ischemic Stroke

    by Romain C. Briest, Kartik D. Bhatia, Christina Miteff, Andrew Cheung, Jayne Antony, Simone Ardern-Holmes, Ann M. Bye, Michael Cardamone, Denise L. Chan, Russell C. Dale, et al.

    BACKGROUND: Thrombolysis is infrequently delivered to children with acute ischemic strokes (AIS). We explored potential eligibility for treatment with tPA (tissue-type plasminogen activator) for pediatric AIS. METHODS: This retrospective, multicenter, observational, cohort study reviewed children aged 29 days to 17 years with symptomatic AIS identified via Children’s Hospital Westmead, John Hunter Children’s Hospital, and Sydney Children’s Hospital between January 1, 2010, and December 31, 2019. Medical records were examined to evaluate eligibility for treatment with tPA based on established multinational and the 2026 American Heart Association guidelines, reasons for exclusion beyond delay to diagnosis, and long-term outcomes as pediatric modified Rankin Scale scores. We also explored additional exclusions and outcomes among children with small-vessel AIS and AIS in the context of brain tumors, who are currently excluded from tPA. RESULTS: A total of 135 patients with 139 symptomatic AIS were identified—median age, 6 years; 36% female patients; 73% presented via emergency departments; mean follow-up, 43 months; 12% deaths. Irrespective of delay to diagnosis, only 26 of 139 (19%) AIS were potentially eligible for treatment with tPA. Among patients potentially eligible for tPA, acute neuroimaging revealed large-vessel occlusions, unilateral focal cerebral arteriopathy, or extracranial dissections. Thirteen of 26 (50%) had nondisabled outcomes without tPA treatment. One hundred thirteen of 139 (81%) AIS were ineligible for treatment with tPA, irrespective of delay to diagnosis. All deaths occurred among patients excluded from tPA, predominantly related to underlying disorders. Fifty-four small-vessel AIS accounted for 39% of AIS. Eighteen (33%) had no additional ineligibilities to thrombolysis, among whom 10 had nondisabled outcomes without tPA. CONCLUSIONS: Based on current recommendations, 19% of symptomatic childhood AIS were potentially eligible for treatment with tPA, irrespective of delay to diagnosis. Selected patients with small-vessel AIS may offer an opportunity to extend the role of tPA. These observations may be relevant for optimizing pediatric stroke management strategies.

  • Open Access

    In situ impedance analysis device for clot characterization in large vessel occlusion acute ischemic stroke, a first-in-human study

    by Andrew Cheung, Henry Rice, Laetitia de Villiers, Nathan W Manning, Suzana Saleme, Vinicius Carraro Do Nascimento, Géraud Forestier, Julie Lafaurie-Janvore, Joachim Rambeau, Franz Bozsak, et al.

    Background: Large vessel occlusion (LVO) stroke is associated with a high risk of permanent disability. There are no reliable tools providing periprocedural information on clot characteristics, such as composition and length, that may impact first pass effect, which has been shown to improve functional outcomes. In the first study of a novel technology, we evaluated whether the Clotild Smart Guidewire System (Clotild), an impedance-based device, can provide in situ information on clot characteristics during a mechanical thrombectomy procedure. Methods: This is the first-in-human, international, multicentric, single-arm trial involving LVO stroke patients. Of 45 enrolled subjects, 41 constituted the safety population; 39 was the per protocol population, of which 26 subjects with complete impedance data comprised the performance population. The latter was divided into development (11 subjects) and validation (15 subjects) populations for prediction model development and assessment. The safety endpoint assessed Clotild-related intracranial vessel perforation/dissection. Performance endpoints evaluated Clotild’s ability to perform classification of impedance measurements distinguishing substantial versus negligible local content in red blood cells (RBCs) and platelets, to detect the arterial wall and the distal end of the clot. Results: The safety endpoint was met in all subjects. Performance analysis comparing the agreement between Clotild’s output and impedance experts’ readings showed an area under the receiver operating characteristic curve (AUC) of 0.97 (95% CI 0.93 to 0.99) for RBC, and 0.94 (95% CI 0.89 to 0.98) for platelet clot composition. Regarding detection, Clotild’s performance showed an AUC of 0.69 (95% CI 0.59 to 0.77) for the arterial wall, and 0.83 (95% CI 0.59 to 1.00) for the distal end of the clot. Conclusions: Clotild was proven safe to acquire impedance data and to provide information on in situ clot characteristics in large vessel occlusions.

  • General vs Nongeneral Anesthesia for Endovascular Thrombectomy in Patients With Large Core Strokes

    by Amrou Sarraj, Spiros Blackburn, Michael G. Abraham, Muhammad S. Hussain, Santiago Ortega-Gutierrez, Michael Chen, Scott E. Kasner, Leonid Churilov, Clark W. Sitton, Deep K. Pujara, et al.

    The association of anesthesia approach during endovascular thrombectomy (EVT) with clinical outcomes in large strokes is unexplored. We aimed to evaluate whether general anesthesia (GA), compared with non-GA, was associated with better functional outcomes in the SELECT2 trial. In a prespecified secondary analysis of the SELECT2 trial that enrolled patients with large strokes on noncontrast CT (Alberta Stroke Program Early CT Score [ASPECTS] 3-5), CT perfusion/MRI (core volume ≥50 mL), or both, functional outcomes were compared in EVT-treated patients who received GA or non-GA and whether this association was modified by stroke severity (NIH Stroke Scale score), ischemic injury estimates, and collateral status was evaluated. The primary outcome was 90-day functional status (ordinal modified Rankin Scale [mRS]). Secondary outcomes were functional independence (mRS scores 0-2), independent ambulation (mRS scores 0-3), complete dependence or death (mRS scores 5-6), and mortality. Of 178 EVT patients (median [interquartile range] age 66 [58-75] years, stroke severity 19 [15-23], CT-ASPECTS 4 [3-5], and core volume 101.5 [70-138] mL, 71 women [39.9%]), 104 (58%) received GA. Time from randomization to arterial puncture was longer with GA (40 [23-59] minutes) vs non-GA (27 [18-47] minutes), but procedural duration (GA: 57 [31.5-77] minutes vs non-GA: 49.5 [30-71] minutes) was similar. Successful reperfusion (modified treatment in cerebral infarction [mTICI] score 2b-3) rates were similar (GA 81 (78%) vs non-GA 62 (84%), adjusted relative risk [aRR] 0.91, 95% CI 0.79-1.06). In addition, mRS distribution did not differ between GA and non-GA groups (adjusted generalized odds ratio 1.21, 95% CI 0.86-1.70), as well as independent ambulation (GA: 41% vs non-GA: 34%, aRR 1.22, 95% CI 0.86-1.74) and functional independence (GA: 22% vs non-GA: 18%, aRR 1.32, 95% CI 0.75-2.35). Stroke severity, ASPECTS, ischemic core volume, or collaterals did not modify the association between anesthesia and functional outcome (all p-interaction >0.05). Patients experienced systolic blood pressure (SBP) variability ≥40 mm Hg and minimum intraprocedural SBP (p-interaction = 0.77 and 0.89, respectively). In patients with large core strokes randomized in SELECT2, EVT outcomes did not differ significantly based on anesthesia approach (GA or non-GA) without heterogeneity across stroke severity and size. While GA was associated with higher SBP variability and lower minimum SBP, this did not modify GA association with functional outcomes. While allocation to anesthesia approach was nonrandomized, our findings suggest that optimizing institutional protocols for preferred anesthesia technique, whether GA or non-GA, may enhance EVT procedural outcomes. ClinicalTrials.gov ID: NCT03876457. This study provides Class II evidence that in patients presenting within 24 hours with large vessel occlusion strokes undergoing EVT, the 90-day mRS score is comparable in those with or without GA.


  • Ultra-Early Hematoma Expansion Is Associated With Ongoing Hematoma Growth and Poor Functional Outcome

    by Chloe A. Mutimer, Teddy Y. Wu, Henry Zhao, Leonid Churilov, Bruce C.V. Campbell, Andrew Cheung, Atte Meretoja, Timothy J. Kleinig, Philip M. Choi, Henry Ma, et al.

    BACKGROUND: There are limited data on ultra-early hematoma growth dynamics and their clinical impact in primary intracerebral hemorrhage (ICH). We aimed to estimate the incidence of hematoma expansion within the hyperacute period of ICH, describe hematoma dynamics over time, investigate the associations between ultra-early hematoma expansion and clinical outcomes after ICH, and assess the effect of tranexamic acid on ultra-early hematoma expansion. METHODS: We performed a preplanned secondary analysis of the STOP-MSU trial (Stopping Intracerebral Hemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units), which compared tranexamic acid with placebo in 201 patients with primary ICH presenting within 2 hours of symptom onset. Repeat computed tomography imaging ≈1 hour after treatment commencement was encouraged (ultra-early reimaging), and patients with this imaging were included in this descriptive study. Imaging analyses were separated into the following time epochs: baseline—the period from onset-to-baseline imaging; ultra-early—the period from baseline imaging to ultra-early reimaging; and interval—the period from ultra-early reimaging to 24-hour reimaging. Hematoma expansion was defined as a ≥33% or ≥6 mL increase from baseline, and functional outcomes were assessed at 90 days (poor functional outcome defined as modified Rankin Scale score of 3–6) using unadjusted logistic regression models. RESULTS: We included 105 patients who had ultra-early reimaging (median age, 66 years; 40% female). Median onset-to-baseline imaging time was 74 minutes (interquartile range, 56–87 minutes), and baseline-to-ultra-early reimaging time was 95 minutes (interquartile range, 74–132 minutes). Forty-one patients (39%) had ultra-early hematoma expansion. These patients had larger baseline hematomas (15.9 mL versus 9.1 mL, P =0.03) compared with those with no early hematoma expansion. Hematoma growth rate declined over time (clustered median regression P P P P P =0.65). CONCLUSIONS: In patients with ICH presenting within 2 hours of symptom onset, most hematoma growth occurs in the ultra-early period. The presence of ultra-early hematoma expansion is associated with ongoing hematoma growth, poor functional outcomes, and mortality and represents a target for therapeutic intervention.


  • Open Access

    Ultra-early hematoma expansion is associated with ongoing hematoma growth and poor functional outcome

    by Chloe A. Mutimer, Teddy Y. Wu, Henry Zhao, Leonid Churilov, Bruce C.V. Campbell, Andrew Cheung, Atte Meretoja, Timothy J. Kleinig, Philip M. Choi, Henry Ma, et al.

    INTRODUCTION There are limited data on ultra-early hematoma growth dynamics and their clinical impact in primary intracerebral hemorrhage (ICH). We aimed to (a) estimate the incidence of hematoma expansion within the hyperacute period of ICH, (b) describe hematoma dynamics over time, (c) investigate the associations between ultra-early hematoma expansion and clinical outcomes after ICH, and (d) assess the effect of tranexamic acid on ultra-early hematoma expansion. METHODS We performed a planned secondary analysis of the STOP-MSU international multicenter randomized controlled trial. The trial compared tranexamic acid with placebo in 201 patients with primary ICH presenting within 2 hours of symptom onset. Repeat CT imaging ∼1 hour after treatment commencement was encouraged. Patients who underwent re-imaging up to 3 hours from baseline imaging were included in this descriptive study. Hematoma expansion was defined as either a ≥33% or ≥6 ml increase from baseline hematoma volume. RESULTS We included 105 of the 201 patients who had 1-hour imaging (median age 66 years, 40% female, 53% tranexamic acid). Median time from onset to baseline imaging was 74min (IQR 56-87 min), and between baseline and 1-hour imaging was 95 min (IQR 74-132 min). Forty-one patients (39%) had ultra-early hematoma expansion. These patients had larger baseline hematoma volumes (15.9 ml vs 9.1 ml, p=0.03) compared to those with no early hematoma expansion. Hematoma growth rate declined over time compared to the onset-to-baseline imaging period (clustered median regression pCONCLUSIONS Most hematoma growth occurs in the ultra-early period. The presence of hyperacute hematoma expansion is associated with ongoing hematoma growth, poor functional outcomes and mortality, and represents a target for therapeutic intervention.

  • Open Access

    WITHDRAWN: Eligibility for thrombolysis and outcome in pediatric acute ischemic stroke

    by Romain C. Briest, Kartik D Bhatia, Christina Miteff, Andrew Cheung, Jayne Antony, Simone Ardern-Holmes, Annie Bye, Michael Cardamone, Denise Chan, Russell Dale, et al.

    Background Thrombolysis is infrequently delivered to children with acute ischemic stroke (AIS). Consideration of eligibility criteria and outcomes after AIS may enhance utility of thrombolysis in pediatric AIS. Methods This retrospective observational study assessed eligibility for acute tissue plasminogen activator (tPA) and outcome in a 10-year population cohort of 151 children with AIS and a first symptomatic AIS cohort of 68 children. Outcomes among children with small vessel AIS, residual brain tumors and intracranial dissection, who are currently excluded from tPA, were explored to assess potential for benefit from tPA in these subgroups. Results Approximately 80% of each cohort were excluded from tPA, irrespective of delay to diagnosis, related to multiple underlying disorders. All deaths occurred among patients excluded from tPA. The minority eligible for tPA had large vessel occlusions, focal cerebral arteriopathy or extracranial dissections. More than half of eligible patients had non-disabled outcomes without tPA. Approximately 40% of both cohorts had small vessel AIS, more than half of whom were excluded from tPA for additional reasons. Among those not additionally excluded, 78-88% of each cohort had non-disabled outcomes without tPA. Among 12 patients excluded from tPA due to residual brain tumors, all had additional exclusions. In contrast, patients with AIS due to intracranial dissection infrequently had additional cause for exclusion and outcomes were relatively poor. Conclusions Only 20% of childhood AISs were eligible for tPA, irrespective of delay to diagnosis, and more than half of these patients manifest non-disabled outcomes without tPA, suggesting relatively restricted potential for benefit with tPA. Relaxation of some exclusions for selected patients may enhance beneficial delivery of tPA.

  • Open Access

    Mechanical Thrombectomy for Pediatric Arterial Ischemic Stroke from Acute M2 Occlusion

    by Kartik D. Bhatia, Elizabeth Pulcine, Ian Andrews, Sachin Gupta, Richard Webster, Christopher Troedson, Russell C. Dale, Michelle Lorentzos, Carmen Parra-Farinas, John Worthington, et al.

    SUMMARY: Pediatric large-vessel occlusion has a poor natural history. Recent retrospective studies have demonstrated the potential benefits, feasibility, and safety profile of mechanical thrombectomy in children. However, the role of thrombectomy in pediatric M2 occlusions remains uncertain. In this clinical report, we present a multicenter series of 6 pediatric patients with acute M2 occlusion (female = 1, male = 5; age range, 0.9–16.0 years, mean = 9.2). All 6 patients having undergone thrombectomy had excellent clinical outcomes (pediatric mRS = 0–1) at 3 months and final available follow-up (median, 12 months; range, 3–72 months). Factors relevant to treatment decision-making in pediatric M2 occlusions are discussed, including the important role of multidisciplinary team discussions during acute management.


  • Open Access

    Most endovascular thrombectomy patients have Target Mismatch despite absence of formal CT perfusion selection criteria

    by Jayden C. Subramaniam, Andrew Cheung, Nathan Manning, Justin Whitley, Dennis Cordato, Alessandro Zagami, Cecilia Cappelen-Smith, Huiqiao Tian, Chris Levi, Mark Parsons, et al.

    Endovascular thrombectomy (EVT) is the standard of care for large vessel occlusion stroke. Use of Computed Tomographic Perfusion (CTP) to select EVT candidates is variable. The frequency of treatment and outcome in patients with unfavourable CTP patterns is unknown. A retrospective analysis of CTP utilisation prior to EVT was conducted. All CTP data were analysed centrally and a Target Mismatch was defined as an infarct core ≤70 ml, penumbral volume ≥15ml, and a total hypoperfused volume:core volume ratio >1.8. The primary outcome was good functional outcome at 90 days, defined as a modified Rankin Scale (mRS) score 0–2. follow-up infarct volume, core expansion and penumbral salvage volumes were secondary outcomes. Of 572 anterior circulation EVT patients, CTP source image data required to generate objective maps were available in 170, and a Target Mismatch was present in 151 (89%). The rate of 90-day good functional outcome was similar between Target Mismatch (53%) and Large Core Non-Mismatch groups (46%, p = 0.629). Median follow-up infarct volume in the Large Core Non-Mismatch group (104ml [IQR 25ml-189ml]) was larger than that in the Target Mismatch patients (16ml [8ml-47ml], p<0.001). Despite a lack of formal CTP selection criteria, the majority of patients treated at our centres had a Target Mismatch. Patients without Target Mismatch had larger follow-up infarct volumes, but the functional recovery rate was similar to that in Target Mismatch patients. Infarct volumes should be included as objective assessment criteria in the evaluation of the efficacy of EVT in non-Target Mismatch patients.


  • Balloon assisted Woven endobridge deployment (BAWD): A safety and efficacy study

    by Anthony Trimboli, Jason D Wenderoth, Andrew K Cheung, Justin Whitley, Alex McQuinn, Cameron Williams, Timothy J Phillips, Jacob Fairhall, Mark Sheridan, Nathan W Manning

    Background: Balloon-assisted deployment/remodelling is a proven adjunctive technique for coil embolization of intracranial aneurysms, and it may be a helpful adjunct in delivering the Woven EndoBridge (WEB) device. Objective: To evaluate the safety, efficacy and feasibility of balloon-assisted WEB deployment in both ruptured and unruptured intracranial aneurysms in both typical and atypical locations. Methods: Patients who underwent treatment of ruptured and unruptured intracranial aneurysms with the BAWD technique were retrospectively identified from a prospectively maintained database at two neurointerventional centres. Patient demographics, aneurysm characteristics, technical procedure details, clinical and imaging outcomes were reviewed. Results: Thirty-three aneurysms (23 women) were identified with a median age of 58 years. There were 15 (45.5%) ruptured aneurysms, 25 (64.3%) in the anterior circulation and 12 (36.4%) aneurysms having an atypical location for WEB treatment. The average aneurysm size was 6.8 mm (greatest dimension), 4.6 mm (height) and 4.5 mm (width), and 25 (75.8%) aneurysms had a wide neck morphology. One patient died (3.0%) secondary to a procedure-related complication, and there was no procedure-related permanent morbidity. Complete and adequate aneurysm occlusion on mid-term follow-up DSA was 85.2% and 92%, respectively. Conclusion: Balloon-assisted WEB deployment appears to be a safe and effective technique that may increase the utility of the WEB device. Further prospective studies on BAWD should be considered.